Biotech IPO Reopening: $1.1B August Wave Ranked

The IPO window is a sentiment gauge, not a strategy. August 2026 just printed the clearest reading of the year: more than $1.1 billion raised across BlossomHill, Latigo, Braveheart, and Attovia in a single week, on top of Apnimed’s $192 million, Scribe’s $128.7 million, and Vogenx’s $81 million. Add a reverse merger and a SPAC, and the message is unambiguous: public investors are funding biotech again. The question that matters is not whether the window is open. It is which of these new listings you would actually own, and which are just open-window froth. The screen is the five-question IPO framework, and the answer splits the class into two tiers.

The De-Risked Tier: Phase 3 Data or a PDUFA Date

Three of the August listings came with something the narrative names do not have: a registrational dataset or a hard FDA date.

Apnimed is the cleanest of the three. It priced at $16, the top of its range, for $192 million, and its lead asset AD109 (Oxnimbi) is the first oral pill for obstructive sleep apnea, backed by two Phase 3 wins: a 46.8% reduction in the apnea-hypopnea index versus 6.8% on placebo in LunAIRo (p < 0.001) and 55.6% versus 19.1% in SynAIRgy (p < 0.0001). The PDUFA date is February 28, 2027. APMD now trades at $27.37, a 71% gain from the IPO price, for a $1.09 billion market cap. This is the difference between betting on an unproven drug and betting on one that already passed its trials and is waiting on a regulator. The full Apnimed breakdown is here.

Latigo is the second name with real data. It raised $345.6 million at $18, and its oral Nav1.8 inhibitor LTG-001 already posted a positive Phase 2 abdominoplasty readout in 343 patients, meeting its primary SPID48 endpoint. The mechanism is validated by Vertex’s already-approved suzetrigine, and the Phase 3 bunionectomy trial starts in the second half of 2026. LTGO trades at $22.57, up 25% from the IPO, for a $1.43 billion market cap. The risk is differentiation against Vertex’s commercial infrastructure, but the target is de-risked. The Latigo pricing story is here.

Braveheart is the momentum trade of the tier. It priced at $18, above its $15 to $17 range, for $382.5 million, and popped 66% to $29.80 on its debut. Its lead asset BHB-1893, a Hengrui-licensed cardiac myosin inhibitor for hypertrophic cardiomyopathy, is Phase 3-ready, with the obstructive HCM study starting later this year. The HCM market already has proof of demand: Bristol Myers’ Camzyos did $416 million in Q2, up 60% year over year. BRVE trades at $27.64, still up 54% from the IPO, for a roughly $1.8 billion market cap. The Braveheart debut is covered here.

The Narrative Tier: Phase 1 Data and a Story

The other four August listings are priced on a mechanism, not a result.

Scribe is the purest narrative name. It raised $128.7 million at $15 for STX-1150, a CRISPR epigenetic silencer of PCSK9, with backing from Lilly and Sanofi and a Nobel pedigree in co-founder Jennifer Doudna. The Phase 1 trial in Australia will not read out until the first half of 2027. The stock ran to $39.60 on August 20 before pulling back to $31.21, still up 108% from the IPO, for a $589 million market cap. That is a company with zero efficacy data trading at more than double its pricing because the sector is hot. The Scribe pricing and the CRISPR thesis are here.

Attovia is the immunology narrative. It raised $289 million at $17, the top of its range, for ATTO-1310, an IL-31 ligand fusion protein for itch. The data so far is a Phase 1b signal where 65% of patients met an itch responder definition at Week 4; the Phase 2 trials do not start until the first half of 2027. ATTO trades at $19.31, up 14% from the IPO for a roughly $830 million market cap. The modest gain suggests the market is not yet convinced by a ligand-versus-receptor differentiation argument against Nemluvio, whose IL-31 receptor blocker is already a $1B-plus drug. The Attovia pricing is here.

BlossomHill raised $150 million at $16 for two oncology programs, both Phase 2 at best: BH-30643, an OMNI-EGFR inhibitor in the Phase 1/2 SOLARA trial (NCT06706076) for EGFR-mutant NSCLC, and BH-30236, a CLK inhibitor for AML. BLSM trades at $18.42, up 15% from the IPO, for a $536 million market cap. The EGFR field is crowded with Tagrisso and Rybrevant, and BlossomHill has to show responses in Tagrisso-resistant patients to earn a registrational path. The BlossomHill pricing is here.

Vogenx is the pure momentum outlier. It raised $81 million at $13 for mizagliflozin, an oral SGLT1 inhibitor for post-bariatric hypoglycemia, and ran 127% on the back of Amylyx’s Phase 3 LUCIDITY win for a rival PBH drug. It now trades at $31.53, up 142% from the IPO, for a $468 million market cap, with the Phase 2b EMERGE readout not due until 2027. A 142% run on a company with no Phase 3 data leaves no room for error. Vogenx (VOGX) mizagliflozin PBH pricing coverage.

The Reverse-Merger and SPAC Wave: Capital Access for Late-Stage Private Assets

The quiet signal of the August window is not a traditional IPO at all. It is the reverse-merger and SPAC revival.

Werewolf Therapeutics handed its Nasdaq listing to Ambros Therapeutics in an all-stock reverse merger that gives Ambros shareholders 71.7% of the combined company and a $150 million PIPE to fund neridronate, a bisphosphonate for complex regional pain syndrome already approved in Italy but with no US clearance. The merged company re-trades as AMBX in 2027. Separately, Oak Hill Bio is going public through a RA Capital SPAC, raising $175 million for rugonersen, an antisense therapy for Angelman syndrome. The Howl/Ambros reverse merger is here and the Oak Hill SPAC is here.

What this tells you is that late-stage private assets that could not clear a traditional IPO bar are finding listings anyway, through shells and SPACs. It is a sign of healthy capital access, but it is also where the worst deals hide. The reverse-merger path rarely produces a clean shareholder structure: the Howl/Ambros split leaves legacy Werewolf holders with 6.8% of a company they did not sign up for.

The Scoreboard and What It Means for Public Comps

The August class has held up so far, but the gains are concentrated in the narrative names, which is exactly backwards. Scribe is up 108% and Vogenx up 142%, while the de-risked Apnimed is up 71%, Latigo 25%, Attovia 14%, and BlossomHill 15%. Momentum is rewarding the stories and underpaying the data. That is a sentiment signal, and it usually does not last.

The framework says the same thing. Apnimed passes all five questions: Phase 3 data, a PDUFA within 12 months, and a valuation that compares cleanly to its sleep-medicine peers. Scribe fails on the first question, Phase 2 data or better. When the lockup expirations start hitting in early 2027, the names that ran on narrative will be the ones that give it back. For the valuation math that separates a $589 million Phase 1 story from a defensible comp, see the biotech valuation guide.

For the broader sector, a reopened window is a rising tide. When public investors fund $1.1 billion of new biotech in a week, the public comps re-rate too, because every new listing is a comparable that can be used to mark up an existing holding. The names to track for IPO exposure without paying the first-day pop are the ones that already passed their trials: Apnimed ahead of its February PDUFA, and Latigo ahead of its Phase 3 start.

Verdict

If you want the reopening trade, own the de-risked tier and rent the narrative tier. Apnimed at $27.37 is the highest-quality name in the class because it has a PDUFA date, not a story, and a $1.09 billion market cap for a first-in-class drug in an 80 million patient market. Latigo is the second choice on a validated target with Phase 2 data. Scribe and Vogenx are trades, not investments: the momentum is real, but a Phase 1 miss or a cooled PBH narrative erases a 100% gain faster than it built. Do not buy a single narrative-tier name above its IPO price, and set calendar reminders for the lockups.